Stock analysts at BTIG Research started coverage on shares of Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) in a research report issued on Friday, Marketbeat Ratings reports. The firm set a "buy" rating and a $42.00 price target on the stock. BTIG Research's price target points to a potential upside of 80.49% from the stock's current price.
Several other brokerages also recently weighed in on ELVN. HC Wainwright restated a "buy" rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird raised their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $38.25.
View Our Latest Analysis on ELVN
Enliven Therapeutics Price Performance
Enliven Therapeutics stock traded up $0.27 during trading hours on Friday, reaching $23.27. The stock had a trading volume of 110,479 shares, compared to its average volume of 253,241. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -12.63 and a beta of 1.02. The business's 50 day moving average price is $26.65 and its 200-day moving average price is $24.16. Enliven Therapeutics has a 52 week low of $10.90 and a 52 week high of $30.03.
Insiders Place Their Bets
In other Enliven Therapeutics news, CFO Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 847 shares of the firm's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $30.00, for a total value of $25,410.00. Following the sale, the insider now directly owns 1,015,188 shares in the company, valued at approximately $30,455,640. This trade represents a 0.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 129,195 shares of company stock valued at $3,581,772. 29.20% of the stock is owned by company insiders.
Institutional Trading of Enliven Therapeutics
Several institutional investors have recently bought and sold shares of the business. FMR LLC increased its stake in shares of Enliven Therapeutics by 10.6% during the third quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after purchasing an additional 601,611 shares in the last quarter. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock worth $26,611,000 after buying an additional 313,019 shares in the last quarter. Geode Capital Management LLC increased its stake in Enliven Therapeutics by 9.9% during the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock worth $19,164,000 after buying an additional 67,813 shares in the last quarter. State Street Corp raised its holdings in shares of Enliven Therapeutics by 2.9% during the third quarter. State Street Corp now owns 745,944 shares of the company's stock valued at $19,051,000 after acquiring an additional 21,018 shares during the last quarter. Finally, First Turn Management LLC lifted its position in shares of Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company's stock valued at $13,666,000 after acquiring an additional 121,849 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
